Skip to main content

Unable to load price data. Sorry.


Plus Therapeutics Inc (NASDAQ:CYTX.DL)

CAPS Rating: No stars

A developing company which seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious, chronic, and life threatening conditions.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:CYTX.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

JGGardner (< 20)
Submitted February 17, 2010

The Regenerative Medicine market is expected to grow to $3 billion by 2015. Cytori Therapeutics (CYTX) is the early leader in this market and is now treating, on a daily basis, more patients than any competing stem cell company. Given the large… More

NeroSagetrade (84.83)
Submitted February 12, 2008

What a staggeringly STAGGERINGLY bad company! The numbers are absolutely obstrusive. These guys could write a book on how to lose money and it would be a best seller. Cytori has lost a whopping 52M in the last 2 years and is sitting on less than 30M… More


  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about CYTX.DL.

No one has written a Pitch for CYTX.DL stock yet. Tell us why you think CYTX.DL will outperform or underperform against the market.


Find the members with the highest scoring picks in CYTX.DL.

No players have picked CYTX.DL yet. Tell us why you think CYTX.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CYTX.DL.